Biotech Values

[EyeamBill]

The FTC won’t allow Teva to buy MNTA—I guarantee it!

I'm less than a novice in such areas but the news of the last few days has me believing that MNTA would be foolish to be acquired by anybody less than a ridiculously handsome premium.

If I had the majority of the voting share then I'd hold out for a sum so large for my shares that any offer would be viewed as bottom-fishing.

Now that the USPTO has applied their stamp (again) then I'd let it ride. There are many more rungs to the ladder than the compounds in the pipeline and m-Copaxone and m-enox. I'm no longer a buy & hold guy, but, there is no other player yet in the micro-industry (a.k.a., solo-industry) that appears to have the infrastructure to reverse-engineer numerous compounds that are losing patent protection in the next decade.

For those whom desire the usual disclaimer; yes, I'm long.

Bill

P.S.: I realize that the USPTO is not judge, jury, and executioner in such matters. I have admittedly lost more than I care to admit in http://superbserv.com/, a micro-company of which I'm both a large shareholder and creditor; it attained a USPTO patent years ago. We have the best technology but improper timing. Sorry Dew, I'm really not trying to sell SuperbServ here; I'm just trying to illustrate that I don't take the USPTO rulings as harbingers for the future. Perhaps we could help you in your meals bet, though!